05.01.14
The issuance of patent #US 8,697,055 B2 protects the use of all Bacillus coagulans probiotic strains such as GanedenBC30, in coffee, tea and cereal applications.
Bacillus coagulans probiotics that have the ability to withstand harsh manufacturing processes, especially those required to make hot tea, coffee and cereal. The effectiveness of these organisms can be linked to its naturally occurring layer of organic material (spore), which protects the genetic core of the bacteria throughout the manufacturing process and the transit in to the gut.
“This patent goes a long way toward supporting our partners in their quest to launch new brands, and revolutionize existing ones,” said Andy Lefkowitz, CEO of Ganeden Biotech. “When combined with the FDA’s No Objection letter on GRAS (safety), 17 studies published in peer reviewed journals, over 100 patents issued around the world and the pending issuance of the first monograph by the USP, we have again demonstrated our commitment to science-based probiotic innovation.”
Bacillus coagulans probiotics that have the ability to withstand harsh manufacturing processes, especially those required to make hot tea, coffee and cereal. The effectiveness of these organisms can be linked to its naturally occurring layer of organic material (spore), which protects the genetic core of the bacteria throughout the manufacturing process and the transit in to the gut.
“This patent goes a long way toward supporting our partners in their quest to launch new brands, and revolutionize existing ones,” said Andy Lefkowitz, CEO of Ganeden Biotech. “When combined with the FDA’s No Objection letter on GRAS (safety), 17 studies published in peer reviewed journals, over 100 patents issued around the world and the pending issuance of the first monograph by the USP, we have again demonstrated our commitment to science-based probiotic innovation.”
